Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Wasp venom offers hope for cancer patients
brazilian wasp
The wasp, native to Brazil, produces a venom containing a cancer-fighting ingredient.

Study shows how toxin selectively attacks cancer cells
 
Scientists say the venom of a Brazilian wasp may one day be used in the fight against cancer.

New research reveals for the first time how a toxin contained in the venom is able to attack cancer cells, leaving normal cells unharmed.

To protect itself from predators, the social wasp Polybia paulista produces a venom containing the toxin MP1 (Polybia-MP1).

Laboratory testing has shown the toxin can inhibit the growth of bladder and prostate cancer cells, as well as the multi-drug resistant leukaemic cells.

Until now it was not understood how MP1 is able to do this without damaging normal cells. But according to new research published in the Biophysical Journal, the toxin selectively attacks lipids that are abnormally distributed across the surface of cancer cells. In a matter of seconds, this creates gaping holes, allowing molecules that are vital for cell function to escape.

Co-author Dr Paul Beales from the University of Leeds said this approach to treatment would be "an entirely new class of anti-cancer drugs" and could help develop new combination therapies, where multiple drugs are used at the same time to attack different parts of the cancer cells.

In future, the researchers plan to alter the amino acid sequence of MP1 to find out more about the peptide's structure, increasing its potential for clinical purposes.

"Understanding the mechanism of action of this peptide will help in translational studies to further assess the potential for this peptide to be used in medicine," Dr Beales explained.

"As it has been shown to be selective to cancer cells and non-toxic to normal cells in the lab, this peptide has the potential to be safe, but further work would be required to prove that."

Image © Prof. Mario Palma/Sao Paulo State University

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.